investor video eXoZymes signifiy a sustainable paradigm shift in chemical production leveraging AI-engineered enzymes Feb 12, 2025 12:15:00 AM
heltzen investor video Looking at the rest of 2025 - part 4 of a fireside chat about Invizyne Feb 11, 2025 6:00:00 AM
heltzen investor video Go To Market Strategy - part 3 of a fireside chat about Invizyne Jan 15, 2025 12:00:00 AM
heltzen investor video Using AI for Enzyme Engineering - Part 2 of a Fireside Chat About Invizyne Jan 7, 2025 12:00:00 AM
heltzen investor video Looking back at 2024 - part 1 of a fireside chat about Invizyne Dec 31, 2024 12:00:00 AM
press release investor video Invizyne’s Nasdaq IPO Marks New Era of Biomanufacturing Nov 13, 2024 12:15:00 AM
investor video Commercializing Invizyne’s cell-free platform - fireside chat with Zachary Karl, PhD, VP of BizDev - and - Lou Basenese Jul 30, 2024 12:00:00 AM
investor video Invizyne IPO: interview with Dr. James J. Lalonde by MDB Capital President and Chief Market Strategist Lou Basenese Jul 17, 2024 12:00:00 AM
investor video CEO Michael Heltzen and Co-Founder & VP of Research Dr. Tyler Korman present the Invizyne story and IPO opportunity to investors Jun 18, 2024 12:00:00 AM
investor video MDB Capital CEO and Invizyne board member, Chris Marlett, presents the Invizyne story and initial public offering (IPO) opportunity to investors via Zoom on June 11, 2024 Jun 11, 2024 12:00:00 AM
.png?width=1024&height=1024&name=Screenshot%202025-01-13%20at%2023.31.19%20(2).png)
.png?width=1024&height=1024&name=Screenshot%202025-01-13%20at%2023.31.07%20(2).png)
.png?width=1024&height=1024&name=Screenshot%202024-12-31%20at%2001.05.49%20(2).png)
.png?width=1024&height=1024&name=Screenshot%202024-12-30%20at%2023.38.58%20(2).png)
